Zentalis Pharmaceuticals (ZNTL) announced the appointment of Iris Roth, PhD, as Chief Operating Officer, COO. Dr. Roth joins Zentalis with over two decades of biopharmaceutical experience building and executing clinical and operational strategies. Dr. Roth joins Zentalis from GlaxoSmithKline (GSK), where she served as Vice President, Medicine Development Leader.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ZNTL:
- Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer
- Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)